# An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

> **NCT06439394** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 52 (actual)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** Optive MEGA-3 (OM3)

## Key facts

- **NCT ID:** NCT06439394
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-17
- **Primary completion:** 2024-07-18
- **Final completion:** 2024-07-18
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06439394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06439394, "An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06439394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*